Australian budget hits device and diagnostics industries
This article was originally published in Clinica
Executive Summary
A restructuring of the product approval fee schedule is expected in Australia following the presentation of the 1996/97 federal budget on August 20th. The Therapeutic Goods Administration aims to achieve 75% cost recovery from industry by 1998/99 and will increase fees in phases as follows: